The Rabies Monoclonal Antibody segmentation by application delineates four primary sub‑markets that together drive the overall market valuation. Human post‑exposure prophylaxis (PEP) accounts for the largest share, reflecting the urgent need for rapid, high‑potency neutralisation of rabies virus following animal bites; this segment contributes roughly 45 % of total revenue due to its widespread adoption in emergency care protocols. Human pre‑exposure prophylaxis (PrEP), primarily targeted at high‑risk occupational groups such as veterinarians and wildlife handlers, represents about 10 % of the market, growing steadily as preventive strategies gain regulatory endorsement. Veterinary prophylaxis, covering both companion animals (dogs, cats) and livestock, supplies approximately 35 % of sales, driven by mandatory vaccination programs and the expanding pet‑care industry. Finally, the research and diagnostics niche, encompassing assay development and experimental therapeutics, holds a modest 10 % share but is critical for pipeline innovation and future market expansion.